STOCK TITAN
  1. Home
  2. Sec-filings
  3. HCAT
  4. [8-K] Health Catalyst, Inc. Reports Material Event

Project Nexus: Health Catalyst (NASDAQ: HCAT) trims workforce and reshapes roles

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Health Catalyst, Inc. announced leadership and workforce changes tied to its Project Nexus restructuring. The Board decided that Chief People Officer Linda Llewelyn will leave that role effective June 1, 2026 as the position is eliminated.

The company and Ms. Llewelyn anticipate a separation agreement and an independent contractor agreement under which she is expected to serve as a senior advisor from June 2, 2026 through September 1, 2026, receiving benefits available under the Executive Severance Plan in exchange for a general release of claims. As part of Project Nexus, the Board also authorized a global workforce reduction expected to cut approximately 9% of employees and remove about 100 additional open, budgeted headcount positions in the US and India.

Positive

  • None.

Negative

  • None.

Insights

Health Catalyst launches cost-focused restructuring, including a 9% workforce cut and CPO role elimination.

Health Catalyst is undertaking Project Nexus, a strategic initiative to simplify its structure and focus resources on its strongest technology opportunities. As part of this effort, the Board authorized a global workforce reduction expected to remove about 9% of employees and approximately 100 additional open roles.

The elimination of the Chief People Officer position and the shift of Linda Llewelyn into a short-term senior advisor role through September 1, 2026 underscore the organizational reset. The company characterizes these actions as a meaningful reduction in its cost structure, with further quantitative detail to come in its next Form 10-Q.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
CPO role end date June 1, 2026 Date Linda Llewelyn ceases as Chief People Officer
Senior advisor period start June 2, 2026 Expected start of independent contractor senior advisor role
Senior advisor period end September 1, 2026 Expected end of senior advisor engagement
Workforce reduction Approximately 9% Expected reduction in global workforce under Project Nexus
Open positions eliminated Approximately 100 positions Additional open, budgeted headcount cut across US and India
Board authorization date April 24, 2026 Date Board authorized the workforce reduction
Project Nexus financial
"As part of Project Nexus, a strategic initiative designed to fundamentally transform the Company's operating model"
Executive Severance Plan financial
"The Company expects the separation agreement will provide Ms. Llewelyn with the separation benefits under the Company’s Executive Severance Plan"
workforce reduction financial
"our Board authorized a workforce reduction on April 24, 2026"
forward-looking statements regulatory
"This on contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Definitive Proxy Statement on Schedule 14A regulatory
"summarized in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission"
Understanding 8-K Material Events →
FALSE000163642200016364222026-04-242026-04-240001636422dei:FormerAddressMember2026-04-242026-04-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________
FORM 8-K
__________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2026
__________________________________________________________
HEALTH CATALYST, INC.
(Exact name of registrant as specified in its charter)
________________________________________________________________
Delaware001-3899345-3337483
(State or other jurisdiction of
incorporation)
(Commission File Number)(IRS Employer
Identification No.)
10897 South River Front Parkway #300
South Jordan, UT 84095
(Address of principal executive offices, including zip code)

(801) 708-6800
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)
______________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
______________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of exchange on which registered
Common Stock, par value $0.001 per shareHCATThe Nasdaq Global Select Market
________________________________________________________
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ((§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 24, 2026, the Board of Directors (our Board) of Health Catalyst, Inc. (the Company) determined that Linda Llewelyn will cease to serve as the Chief People Officer of the Company effective June 1, 2026 due to the elimination of the Chief People Officer role in connection with the workforce reduction described in this Current Report on Form 8-K. In order to enable a smooth transition of her prior responsibilities as Chief People Officer, the Company and Ms. Llewelyn anticipate entering into a separation agreement and an independent contractor agreement pursuant to which Ms. Llewelyn is expected to serve as a senior advisor starting June 2, 2026 through September 1, 2026. The Company expects the separation agreement will provide Ms. Llewelyn with the separation benefits under the Company’s Executive Severance Plan, which are summarized in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on May 19, 2025, in exchange for a general release of claims against the Company.

Item 8.01 Other Events.

As part of Project Nexus, a strategic initiative designed to fundamentally transform the Company's operating model, simplify its organizational structure, and align resources around its highest-conviction technology opportunities, our Board authorized a workforce reduction on April 24, 2026. The Company expects this initiative to reduce its global workforce by approximately 9% and eliminate approximately 100 additional open, budgeted headcount positions across the US and India, collectively representing a meaningful reduction in the Company's cost structure. The Company will provide further details regarding the impact of this initiative in its upcoming Quarterly Report on Form 10-Q.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the entry into a separation agreement and an independent contractor agreement with Ms. Llewelyn and statements regarding the implementation and intended effect of the global workforce reduction and the timing and anticipated size of the related reduction of the Company’s global workforce. Any forward-looking statements contained in this Current Report on Form 8-K are based upon the Company’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent the Company’s expectations as of the date of this Current Report on Form 8-K, and involve risks, uncertainties, and assumptions. The actual results may differ materially from those anticipated in the forward-looking statements as a result of numerous factors, many of which are beyond the control of the Company, including the risks and uncertainties disclosed in the Company’s reports filed from time to time with the Securities and Exchange Commission, including its most recent Form 10‑K and any subsequent filings on Forms 10-Q or 8-K, available at www.sec.gov. Except as required by law, the Company does not intend to update any forward-looking statement contained in this Current Report on Form 8-K to reflect events or circumstances arising after the date hereof.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.
Exhibit No.Description
104Cover page Interactive Data File (embedded within the Inline XBRL document)
10.1#*
Form of Indemnification Agreement, between Health Catalyst, Inc. and each of its executive officers and directors
10.2#**
Non-Employee Director Compensation Policy
10.3#***
Executive Severance Plan
* Incorporated by reference to Exhibit 10.18 on the Form S-1 filed June 27, 2019
** Incorporated by reference to Exhibit 10.1 to the Form 10-K/A filed April 30, 2025.
*** Incorporated by reference to Exhibit 10.16 to the Form S-1/A filed July 12, 2019
# Indicates management contract or compensatory plan.



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTH CATALYST, INC.
Date: April 27, 2026By:/s/ Jason Alger
Jason Alger
Chief Financial Officer


Source: View Original Filing on SEC EDGAR

FAQ

What workforce changes did Health Catalyst (HCAT) announce in this 8-K?

Health Catalyst’s Board authorized a global workforce reduction tied to Project Nexus. The company expects to reduce its global workforce by approximately 9% and eliminate about 100 additional open, budgeted headcount positions across the US and India, describing this as a meaningful reduction in its cost structure.

Who is leaving the Chief People Officer role at Health Catalyst (HCAT)?

Linda Llewelyn will cease serving as Chief People Officer effective June 1, 2026. The role is being eliminated in connection with the workforce reduction, and she is expected to continue as a senior advisor under an independent contractor agreement through September 1, 2026.

What is Project Nexus at Health Catalyst (HCAT)?

Project Nexus is a strategic initiative to transform Health Catalyst’s operating model. It is intended to simplify the organizational structure and align resources around the company’s highest-conviction technology opportunities, and includes a global workforce reduction and removal of additional open positions in the US and India.

Will Health Catalyst’s former Chief People Officer receive severance benefits?

Health Catalyst expects to provide Linda Llewelyn benefits under its Executive Severance Plan. The company anticipates entering a separation agreement granting those benefits in exchange for a general release of claims, consistent with terms summarized in its previously filed Definitive Proxy Statement on Schedule 14A.

How long will Linda Llewelyn remain involved with Health Catalyst (HCAT)?

Linda Llewelyn is expected to serve as a senior advisor from June 2 to September 1, 2026. This would occur under an anticipated independent contractor agreement, helping transition her former Chief People Officer responsibilities following elimination of the role.

When will Health Catalyst (HCAT) provide more details on the restructuring impact?

Health Catalyst plans to share more information in its upcoming Form 10-Q. The company states that it will provide further details regarding the impact of the Project Nexus workforce reduction in its next quarterly report filed with the Securities and Exchange Commission.

Filing Exhibits & Attachments

4 documents

Other Documents